The Treat Stroke to Target trial 3.5-year follow-up data were presented by Prof. Pierre Amarenco (Xavier Bichat Medical School and Denis Diderot University, France) [1]. This open-label trial randomised patients who had had an atherothrombotic ischaemic stroke in the past 3 months or a transient ischaemic attack (TIA) in the past 15 days (n=2,860) to either a LDL-C target of <70 mg/dL or a target of 100 mg/dL (±10 mg/dL) using statins and/or other lipid lowering therapy (e.g. ezetimibe).
The primary endpoint was a composite of ischaemic stroke, myocardial infarction (MI), new symptoms requiring urgent coronary or carotid revascularisation, and death. The primary endpoint occurred in 8.5% patients in the arm targeting <70 mg/dL versus 10.9% of patients in the target 100 mg/dL arm (adjusted HR 0.78; 95% CI 0.61-0.98; P=0.036; see Table). A large number of secondary endpoints were also evaluated (see Table).
Table: Primary and secondary endpoint results comparing the 2 LDL-C targets of the Treat Stroke to Target trial [1]

** P-values for additional secondary endpoints were not calculated, as there was no significant between-group difference for the first endpoint on hierarchical testing.HR, hazard ratio; LDL-C, low-density lipoprotein cholesterol; TIA, transient ischaemic attack.
The authors concluded that after an atherothrombotic ischaemic stroke, targeting LDL-C <70 mg/dL lowered the risk for CV events more than the 100±10 mg/dL target. The results were recently published in full in the New England Journal of Medicine [2].
- Amerenco P, et al. Treat stroke to target- Benefit of a target LDL cholesterol less than 70 mg/dl after ischemic stroke due to atherosclerosis. LBS06, AHA Scientific Sessions 2019, 14-18 November, Philadelphia, USA.
- Amarenco P, et al. A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke. N Engl J Med 2020 Jan 2;382(1):9.
Posted on
Previous Article
« Intra-aortic balloon pump better than Impella: new observational data Next Article
PARAGON-HF: Benefits for women and lower ejection fraction »
« Intra-aortic balloon pump better than Impella: new observational data Next Article
PARAGON-HF: Benefits for women and lower ejection fraction »
Table of Contents: AHA 2019
Featured articles
New Approaches to CVD Risk Reduction
Phase 3 BETonMACE trial did not meet its primary endpoint
Inclisiran safely halves LDL-Cholesterol
Colchicine prevents cardiovascular events
Interventional Management for Acute Coronary Syndrome
Drop aspirin after 3 months in non-STEMI ACS patients on dual antiplatelet therapy
Immediate coronary angiography after cardiac arrest does not improve survival
Complete revascularisation for obstructive non-culprit lesions with vulnerable plaque
Colchicine: no difference in peri-procedural cardiovascular events 30 days post-PCI
Intra-aortic balloon pump better than Impella: new observational data
Results for the Ischemia Trials: To Intervene or Not to Intervene
ISCHEMIA trial: Invasive treatment only better for angina burden
Controversies in Contemporary Management of Aortic Stenosis
Full GALILEO results: Why did rivaroxaban fail after TAVR?
Balloon-expandable better than self-expanding transcatheter heart valves
RECOVERY: Benefit of early surgery in asymptomatic severe aortic stenosis
Guidelines: Updates and Controversies
New guidelines on the prevention of cardiovascular conditions
Trials in Electrophysiology and Left Ventricular Function
RENAL-AF trial: Apixaban similar to warfarin
Apple Heart Study: Not just for atrial fibrillation
Early apixaban safe as secondary prevention of stroke from AF
Carvedilol does not improve exercise performance in Fontan patients
New Frontiers in Lipid Therapy
Icosapent ethyl plus statins reduces total plaque volume
ORION-9: Inclisiran RNAi halves LDL in familial hypercholesterolaemia patients
New RNAi therapies to reduce triglycerides: 2 studies show favourable results
Targeting LDL-C <70 mg/dL is better than 100 mg/dL after stroke
Challenges in Heart Failure Management
FUEL trial: Udenafil improves some exercise measurements in Fontan
DAPA-HF: Dapagliflozin also good for heart failure patients without diabetes, of any age, or any health status
PARAGON-HF: Benefits for women and lower ejection fraction
Related Articles
February 26, 2020
Targeting LDL-C <70 mg/dL is better than 100 mg/dL after stroke
February 26, 2020
Carvedilol does not improve exercise performance in Fontan patients

February 26, 2020
Editor Biography
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com